SCHEMBL285379

SCHEMBL285379

CCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F

nearest known ligand 0.87

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.87
ADK P55263 6/20 0.54
SMN1; SMN2 Q16637 2/20 0.47
TSHR P16473 1/20 0.47
MAPT P10636 1/20 0.47
PMP22 Q01453 1/20 0.47
HBB P68871 1/20 0.47
P2RY6 Q15077 2/20 0.38
P2RY14 Q15391 2/20 0.38
NT5E P21589 1/20 0.38
ADORA3 P0DMS8 1/20 0.35
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8193596 1.00 LMNA (0.87) LMNAADKSMN1; SMN2TSHRMAPT
SCHEMBL8425098 0.94 LMNA (0.94) LMNAADKSMN1; SMN2TSHRMAPT
SCHEMBL13394000 0.94 LMNA (0.94) LMNAADKSMN1; SMN2TSHRMAPT
SCHEMBL6420868 0.94 LMNA (0.94) LMNAADKSMN1; SMN2TSHRMAPT
SCHEMBL8966859 0.94 LMNA (0.94) LMNAADKSMN1; SMN2TSHRMAPT
Capecitabine SCHEMBL12302025 0.93 LMNA (1.00) LMNAADKSMN1; SMN2TSHRMAPT
Capecitabine SCHEMBL2470888 0.93 LMNA (1.00) LMNAADKSMN1; SMN2TSHRMAPT
Capecitabine SCHEMBL21152105 0.93 LMNA (1.00) LMNAADKSMN1; SMN2TSHRMAPT
Capecitabine SCHEMBL2184820 0.93 LMNA (1.00) LMNAADKSMN1; SMN2TSHRMAPT
Capecitabine SCHEMBL4939140 0.93 LMNA (1.00) LMNAADKSMN1; SMN2TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2428213-A1 STABILIZED CHLORITE SOLUTIONS IN COMBINATION WITH FLUOROPYRIMIDINES FOR USE IN CANCER TREATMENT Nuvo Research AG (CH) 2012-03-14 EP claimed
EP-1758860-B1 SATURATED AND UNSATURATED 3-PYRIDYL-BENZOCYCLOALKYLMETHYL-AMINES FOR USE IN THE TREATMENT OF PAINS, DEPRESSIONS AND ANXIETY STATES GRUENENTHAL GMBH (DE) 2009-09-02 EP claimed
EP-0882734-B1 5'-Deoxy-cytidine derivatives HOFFMANN LA ROCHE (CH) 2009-08-26 EP claimed
EP-1060183-B1 5'-DEOXYCYTIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2003-04-23 EP claimed
US-6211166-B1 COADMINISTERED WITH A 5-FLUOROURACIL DERIVATIVE; ANTICARCINOGENIC AGENTS HOFFMAN-LA ROCHE INC. 2001-04-03 US claimed
EP-1060183-A1 5'-DEOXYCYTIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-12-20 EP claimed
WO-1999040099-A1 5'-DEOXYCYTIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1999-08-12 WO claimed
EP-0882734-A2 5'-Deoxy-cytidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 1998-12-09 EP claimed
EP-0602454-B1 N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines HOFFMANN LA ROCHE (CH) 1996-04-24 EP claimed
EP-0602454-A1 N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines F. HOFFMANN-LA ROCHE AG (CH) 1994-06-22 EP claimed
WO-2023193665-A1 EXTRACELLULAR VESICLE-BASED ESTERASE-RESPONSIVE DRUG DELIVERY CARRIER, METHOD FOR PREPARING SAME, AND USE THEREOF 威海纽兰生物科技有限公司 2023-10-12 WO disclosed
EP-2428213-A1 STABILIZED CHLORITE SOLUTIONS IN COMBINATION WITH FLUOROPYRIMIDINES FOR USE IN CANCER TREATMENT Nuvo Research AG (CH) 2012-03-14 EP disclosed
EP-1758860-B1 SATURATED AND UNSATURATED 3-PYRIDYL-BENZOCYCLOALKYLMETHYL-AMINES FOR USE IN THE TREATMENT OF PAINS, DEPRESSIONS AND ANXIETY STATES GRUENENTHAL GMBH (DE) 2009-09-02 EP disclosed
EP-0882734-B1 5'-Deoxy-cytidine derivatives HOFFMANN LA ROCHE (CH) 2009-08-26 EP disclosed
EP-1060183-B1 5'-DEOXYCYTIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2003-04-23 EP disclosed
EP-0882734-A2 5'-Deoxy-cytidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 1998-12-09 EP disclosed
EP-0828508-A2 COMPOSITIONS OF INTERLEUKIN AND PYRIMIDINE NUCLEOSIDES F. HOFFMANN-LA ROCHE AG (CH) 1998-03-18 EP disclosed
WO-1996037214-A2 COMPOSITIONS OF INTERLEUKIN AND PYRIMIDINE NUCLEOSIDES F. HOFFMANN-LA ROCHE AG (CH) 1996-11-28 WO disclosed
EP-0602454-B1 N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines HOFFMANN LA ROCHE (CH) 1996-04-24 EP disclosed
EP-0602454-A1 N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines F. HOFFMANN-LA ROCHE AG (CH) 1994-06-22 EP disclosed